What is Ionis Pharmaceuticals's revenue?

Ionis Pharmaceuticals (IONS) generated $1.1B in revenue over the trailing twelve months, up 47.5% year over year.

Is Ionis Pharmaceuticals profitable?

Ionis Pharmaceuticals is not currently profitable: it reported a net loss of $327.0M over the trailing twelve months, a -30.9% net margin.

What are Ionis Pharmaceuticals's profit margins?

Gross margin is 98.4% and operating margin is -33.3%, with a -30.9% net margin.

What is Ionis Pharmaceuticals's earnings per share?

Ionis Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.07.

Where does Ionis Pharmaceuticals's income statement data come from?

Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Ionis Pharmaceuticals IONS Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$246.09M+21.0%	$203.33M+29.7%	$156.72M-65.3%	$452.05M+243%	$131.61M-41.9%
Total cost of revenue	$2.98M-62.5%	$7.96M+240%	$2.34M-43.7%	$4.15M+184%	$1.46M-61.8%
Gross profit	$243.11M+24.4%	$195.37M+26.6%	$154.38M-65.5%	$447.9M+244%	$130.15M-41.6%
Gross margin	98.8%+2.7pp	96.1%-2.4pp	98.5%-0.6pp	99.1%+0.2pp	98.9%+0.6pp
Research and development	——	$228.9M0.0%	$228.9M0.0%	$228.9M0.0%	$228.9M+1.6%
Selling, general and administrative	$150.36M+15.5%	$130.19M+34.5%	$96.81M+6.8%	$90.62M+18.8%	$76.25M-13.4%
Compensation and benefits	$43.28M-0.1%	$43.32M+39.1%	$31.15M+4.9%	$29.69M-0.1%	$29.72M-17.8%
Occupancy and equipment	——	$6.5M0.0%	$6.5M0.0%	$6.5M0.0%	$6.5M+12.1%
Depreciation and amortization	$661K+3.6%	$638K+2.7%	$621K+3.8%	$598K+2.7%	$582K+26.8%
Other operating expenses	——	-1.1%—	——	——	——
Total costs & expenses	$363.52M-13.0%	$417.79M+31.8%	$316.9M+1.5%	$312.23M+12.1%	$278.47M-17.5%
Operating income	-$117.42M+45.2%	-$214.46M-33.9%	-$160.18M-215%	$139.82M+195%	-$146.86M-32.5%
Operating margin	-47.7%+57.8pp	-105.5%-3.3pp	-102.2%-133pp	30.9%+143pp	-111.6%-62.7pp
Interest expense	$5.16M+6.9%	$4.83M+14.6%	$4.21M+2.4%	$4.11M+0.1%	$4.11M-2.0%
Interest income	$25.48M+3.0%	$24.73M+4.4%	$23.68M-4.1%	$24.69M+0.1%	$24.67M-14.7%
Other income (expense), net	-$456K+97.2%	-$16.29M-4,587%	$363K+256%	$102K-78.1%	$465K+54.0%
Gain (loss) on disposal of assets	$22.58M—	——	$29.91M+263%	-$18.31M-746%	-$2.16M+69.4%
Net investment gains (losses)	$22.58M—	$0-100%	$29.91M+261%	-$18.62M-907%	-$1.85M+28.1%
Income before income taxes	-$92.31M+59.5%	-$227.92M-77.5%	-$128.39M-204%	$123.53M+184%	-$146.82M-37.2%
Income tax expense	$218K-85.3%	$1.48M+594%	$213K+1,165%	-$20K-117%	$116K+104%
Net income	-$92.53M+59.7%	-$229.39M-78.4%	-$128.61M-204%	$123.55M+184%	-$146.94M-40.8%
Net margin	-37.6%+75.2pp	-112.8%-30.8pp	-82.1%-109pp	27.3%+139pp	-111.6%-65.6pp
Diluted earnings per share	-$0.56+60.3%	-$1.41-76.2%	-$0.80-214%	$0.70+175%	-$0.93-40.9%
Basic earnings per share	-$0.56+60.3%	-$1.41-76.2%	-$0.80-203%	$0.78+184%	-$0.93-40.9%
Weighted-average shares, diluted	164.9M+3.0%	160M+0.2%	159.8M-12.4%	182.3M+14.9%	158.7M+6.2%
Weighted-average shares, basic	164.9M+3.0%	160M+0.2%	159.8M+0.4%	159.1M+0.3%	158.7M+6.2%
Accretion (Amortization) of Discounts and Premiums, Investments	$6.19M+9.1%	$5.67M+11.5%	$5.09M-13.4%	$5.87M-17.4%	$7.11M-24.8%
Adjustments To Additional Paid In Capital Inducement Related To Repurchase Of Convertible Senior Notes	——	$12.92M0.0%	$12.92M0.0%	$12.92M0.0%	$12.92M—
Share-based compensation expense related to employee stock plans	$43.29M-0.9%	$43.68M+38.3%	$31.58M+4.6%	$30.2M0.0%	$30.21M-17.1%
Pre-tax stock-based compensation cost	$43.28M-0.1%	$43.32M+39.1%	$31.15M+4.9%	$29.69M-0.1%	$29.72M-17.8%
Amortization Of Financing Costs	$2.35M+19.4%	$1.97M+19.1%	$1.65M+0.4%	$1.65M+0.2%	$1.64M-1.9%
Amortization of capitalized software and acquired intangible assets	$661K+3.6%	$638K+2.7%	$621K+3.8%	$598K+2.7%	$582K+26.8%
Capital And Patent Expenditures Incurred But Not Yet Paid	$1.04M—	——	$333K—	——	$460K—
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	-$198.88M-686%	$33.92M-17.3%	$41.04M+23.9%	$33.11M+49.7%	$22.12M+124%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$98.27M+57.0%	-$228.7M-80.6%	-$126.6M-202%	$124.51M+186%	-$145.08M-30.7%
Federal	——	-$253.75K0.0%	-$253.75K0.0%	-$253.75K0.0%	-$253.75K+81.5%
Foreign	——	$55.25K0.0%	$55.25K0.0%	$55.25K0.0%	$55.25K+30.8%
Current Income Tax Expense Benefit Utilization Of State Tax Loss Carryforwards	——	——	——	——	——
Federal	——	$0—	$0—	$0—	$0—
State	——	$0—	$0—	$0—	$0—
Depreciation	$3.3M+1.3%	$3.26M+44.5%	$2.26M-0.5%	$2.27M+1.7%	$2.23M-0.5%
Early Repayment Of Convertible Debt	——	$66.91M0.0%	$66.91M0.0%	$66.91M0.0%	$66.91M—
Effect of exchange rate changes on cash and cash equivalents, including restricted cash	——	$175.5K0.0%	$175.5K0.0%	$175.5K0.0%	$175.5K+357%
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	-$138K—	——	——	$595K+156%	$232K+148%
Effective tax rates	——	-$0.01-300%	-$00.0%	-$00.0%	-$0-110%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	-24.7%—	——	——	——
Effect of cross-border tax laws	——	$114.75K0.0%	$114.75K0.0%	$114.75K0.0%	$114.75K—
Effect of cross-border tax laws	——	-0.1%—	——	——	——
Effective Income Tax Rate Reconciliation, FDII, Amount	——	——	——	——	——
Effective Income Tax Rate Reconciliation, FDII, Percent	——	——	——	——	——
Foreign operations	——	0%—	——	——	——
Effective Income Tax Rate Reconciliation Nondeductible Expense Excess Compensation Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation Nondeductible Expense Excess Compensation Amount	——	——	——	——	——
Other	——	-$00.0%	-$00.0%	-$00.0%	-$0—
Effective Income Tax Rate Reconciliation Orphan Drug Tax Credits Percent	——	-8%—	——	——	——
Effective Income Tax Rate Reconciliation Orphan Drug Tax Credits Amount	——	-$7.63M0.0%	-$7.63M0.0%	-$7.63M0.0%	-$7.63M—
Changes in unrecognized tax benefits	——	-3.2%—	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Percent	——	——	——	——	——
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount	$18K-94.9%	$355K-18.4%	$435K-14.5%	$509K+3.7%	$491K+67.6%
Impairment of intangible assets	$40K-99.1%	$4.63M+217%	-$3.94M-1,769%	$236K+287%	$61K-97.0%
Federal taxes	——	-$9.25K0.0%	-$9.25K0.0%	-$9.25K0.0%	-$9.25K—
Foreign	——	$11.5K0.0%	$11.5K0.0%	$11.5K0.0%	$11.5K—
State taxes	——	-$162K0.0%	-$162K0.0%	-$162K0.0%	-$162K—
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	$23.44M0.0%	$23.44M0.0%	$23.44M0.0%	$23.44M-38.5%
Income Tax Reconciliation Change In Enacted Tax Rate	——	——	——	——	——
Income Tax Reconciliation Foreign Income Tax Rate Differential	——	-$29.5K0.0%	-$29.5K0.0%	-$29.5K0.0%	-$29.5K-887%
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	-$19.93M0.0%	-$19.93M0.0%	-$19.93M0.0%	-$19.93M+17.5%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	——	$1.05M0.0%	$1.05M0.0%	$1.05M0.0%	$1.05M+2,126%
Share-based compensation	——	$4.82M0.0%	$4.82M0.0%	$4.82M0.0%	$4.82M+79.5%
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	-$72K0.0%	-$72K0.0%	-$72K0.0%	-$72K-143%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	$88.25K0.0%	$88.25K0.0%	$88.25K0.0%	$88.25K+103%
Changes in unrecognized tax benefits	——	$3.04M0.0%	$3.04M0.0%	$3.04M0.0%	$3.04M—
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$4.44M0.0%	$4.44M0.0%	$4.44M0.0%	$4.44M—
Income Taxes Paid, Net	-$8K—	——	-$278K—	——	-$400K+94.8%
Accounts payable	-$3.1M—	——	-$8.81M—	——	-$25.97M-174%
Increase Decrease In Accrued Income Taxes Payable	$161K—	——	$20K—	——	$92K—
Increase (Decrease) in Contract with Customer, Asset	$7.63M—	——	-$27.97M—	——	-$52.48M—
Increase (decrease) in contract liabilities and current deferred income	-$20.82M-8.8%	-$19.13M-18.7%	-$16.11M+22.4%	-$20.77M-51.4%	-$13.72M+4.1%
Increase Decrease In Escrow Deposits	$632.51M—	——	——	——	——
Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable	——	$669.75K0.0%	$669.75K0.0%	$669.75K0.0%	$669.75K+227%
Increase (Decrease) in Inventories	-$338K—	$0-100%	$2.14M-84.2%	$13.48M+1,434%	-$1.01M-120%
Increase (decrease) in other current liabilities	$21M—	——	$84.15M+2,528%	$3.2M+862%	$333K+102%
Increase Decrease In Other Employee Related Liabilities	-$80.19M-235%	$59.22M—	——	——	-$43.04M-248%
Increase (Decrease) in Other Operating Assets	$7.39M—	——	$100.95M+893%	$10.17M-17.8%	$12.37M-30.1%
Debt conversion inducement expense	——	$4.09M0.0%	$4.09M0.0%	$4.09M0.0%	$4.09M—
Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties	$17.34M-2.9%	$17.86M-0.5%	$17.95M-3.7%	$18.65M-0.9%	$18.82M+0.8%
Interest Expense Related To Sale Of Future Royalties	$17.18M-3.0%	$17.71M-0.5%	$17.8M-3.8%	$18.5M-0.9%	$18.67M+0.8%
Interest Paid, Excluding Capitalized Interest, Operating Activity	$90K-98.3%	$5.38M+2,810%	$185K-96.4%	$5.12M+5,467%	$92K-98.2%
Net interest and investment income (loss)	$25.48M+3.0%	$24.73M+4.4%	$23.68M-4.1%	$24.69M+0.1%	$24.67M-14.7%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$57.26M-90.3%	$591.18M+628%	$81.22M+6,413%	$1.25M-43.3%	$2.2M—
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	$536.82M+228%	-$419.51M-559%	$91.34M+176%	-$120.07M-170%	$170.46M—
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$792.82M-476%	-$137.71M-4.8%	-$131.44M-187%	$151.34M+200%	-$150.78M-29.8%
Number Of Major European Countries	5—	——	——	——	——
Number Of Purchased Facilities Financed With Mortgage Debt	——	——	——	——	——
Number Of Quarters After Billing When Payment Is Received	——	0.30.0%	0.30.0%	0.30.0%	0.3—
Number of reportable segments	1+300%	0.30.0%	0.30.0%	0.30.0%	0.3—
Occupancy and Related Charges	——	$6.5M0.0%	$6.5M0.0%	$6.5M0.0%	$6.5M+12.1%
Operating Lease Payments	——	$6.1M0.0%	$6.1M0.0%	$6.1M0.0%	$6.1M+19.0%
Operating lease right-of-use assets amortization expense	$3.49M+1.2%	$3.44M+112%	$1.63M-37.2%	$2.59M+0.1%	$2.59M+0.7%
Net unrealized gains (losses) on securities still held	-$5.6M-857%	$740K-64.6%	$2.09M+470%	$367K-77.5%	$1.63M—
Other income, net (Note 6)	-$456K+97.2%	-$16.29M-4,587%	$363K+256%	$102K-78.1%	$465K+54.0%
Patent Expenses	——	$1.6M0.0%	$1.6M0.0%	$1.6M0.0%	$1.6M+20.8%
Payments For Transaction Costs Related To Sale Of Future Royalties	——	$0—	$0—	$0—	$0—
Payments to Acquire Debt Securities, Available-for-Sale	$192.76M-75.7%	$791.97M+144%	$323.94M-34.1%	$491.59M+58.0%	$311.07M-6.8%
Payments to Acquire Intangible Assets	$1.49M+8.9%	$1.37M-17.8%	$1.66M-15.5%	$1.96M+202%	$651K-74.4%
Payments to Acquire Property, Plant, and Equipment	$21.76M+2.2%	$21.29M+304%	$5.27M-57.2%	$12.31M-2.2%	$12.58M-50.7%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options	$57.3M-46.9%	$107.82M+32.7%	$81.26M+6,214%	$1.29M-42.6%	$2.24M+457%
Proceeds From Real Estate Transaction	——	$0—	$0—	$0—	$0—
Proceeds from sales and redemptions of investments in debt securities classified as available for sale	$752.82M+90.5%	$395.12M-6.4%	$422.21M+9.4%	$385.79M-22.0%	$494.76M+15.1%
Proceeds From Sale Of Future Royalties	——	$0—	$0—	$0—	$0—
Dispositions of property, plant, and equipment	——	——	$19.6M—	——	——
Gross realized gains (losses)	$22.58M—	$0-100%	$29.91M+261%	-$18.62M-907%	-$1.85M+28.1%
Repayments of Secured Debt	$44K-15.4%	$52K+26.8%	$41K+2.5%	$40K-4.8%	$42K+2.4%
Research Development And Patent Expense	$210.17M—	——	$217.75M+0.1%	$217.46M+8.3%	$200.76M-18.2%
Revenue From Contract With Customer Excluding Assessed Tax	$246.09M+21.0%	$203.33M+29.7%	$156.72M-65.3%	$452.05M+243%	$131.61M-41.9%
Royalty Payments	$11.69M-16.4%	$13.97M+2.9%	$13.58M+13.2%	$12M-6.9%	$12.89M-11.5%
Stock-based compensation	$43.28M-0.1%	$43.32M+39.1%	$31.15M+4.9%	$29.69M-0.1%	$29.72M-17.8%
Total stock-based compensation expense included in “Total costs and expenses”	$43.29M-0.9%	$43.68M+38.3%	$31.58M+4.6%	$30.2M0.0%	$30.21M-17.1%
Stock Issued During Period Value Share Based Compensation Gross	$57.3M-46.9%	$107.82M+32.7%	$81.26M+6,219%	$1.29M-42.6%	$2.24M+458%
Interest expense and penalties, net (benefit)/charge recognized	——	$25K0.0%	$25K0.0%	$25K0.0%	$25K0.0%
Additions for tax positions of prior years	——	$1.44M0.0%	$1.44M0.0%	$1.44M0.0%	$1.44M+204%
Upfront Royalty Payment Received	——	——	——	——	——
Valuation Allowances And Reserves Period Increase Decrease	——	$26.75M0.0%	$26.75M0.0%	$26.75M0.0%	$26.75M—
EBIT	-$117.42M+45.2%	-$214.46M-33.9%	-$160.18M-215%	$139.82M+195%	-$146.86M-32.5%
EBITDA	-$113.46M+46.1%	-$210.56M-33.9%	-$157.31M-210%	$142.68M+199%	-$144.05M-33.2%
EBITDA	-$113.46M+46.1%	-$210.56M-33.9%	-$157.31M-210%	$142.68M+199%	-$144.05M-33.2%
EBITDA margin	-46.1%+57.5pp	-103.6%-3.2pp	-100.4%-132pp	31.6%+141pp	-109.5%-61.7pp
EBIT	-$117.42M+45.2%	-$214.46M-33.9%	-$160.18M-215%	$139.82M+195%	-$146.86M-32.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Ionis Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ionis Pharmaceuticals's revenue?: Ionis Pharmaceuticals (IONS) generated $1.1B in revenue over the trailing twelve months, up 47.5% year over year.
Is Ionis Pharmaceuticals profitable?: Ionis Pharmaceuticals is not currently profitable: it reported a net loss of $327.0M over the trailing twelve months, a -30.9% net margin.
What are Ionis Pharmaceuticals's profit margins?: Gross margin is 98.4% and operating margin is -33.3%, with a -30.9% net margin.
What is Ionis Pharmaceuticals's earnings per share?: Ionis Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.07.
Where does Ionis Pharmaceuticals's income statement data come from?: Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.